Research Abstracts, Phase 2 Results, and Market Availability of Formulations and Treatments- Research Report on Teva, Forest, Pharmacyclics, Cubist, and Dr. Reddy's Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, June 19, 2013 NEW YORK, June 19, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Forest Laboratories, Inc. (NYSE: FRX), Pharmacyclics, Inc. (NASDAQ: PCYC), Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), and Dr. Reddy's Laboratories Limited (NYSE: RDY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Teva Pharmaceuticals Industries Ltd Research Report On June 14, 2013, Teva Pharmaceuticals Industries Ltd (Teva) announced that the Company will present a number of abstracts during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders, held in Sydney, Australia from June 16 to June 20, 2013. The Company affirmed that these presentations will reflect Teva's ongoing commitment to Parkinson's Disease (PD) research and underscore the potential of AZILECT as a treatment modality for PD. "We are committed to driving advances in research to help address the treatment needs of those impacted by neurological conditions," said Michael Hayden, MD, President of Global R&D and Chief Scientific Officer at Teva. The Full Research Report on Teva Pharmaceuticals Industries Ltd - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/e4ac_TEVA] -- Forest Laboratories,Inc. Research Report On June 13, 2013, Forest Laboratories, Inc. (Forest) announced the availability of NAMENDA XR (memantine hydrochloride) once-daily formulation, in pharmacies throughout the United States. NAMENDA XR is approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer's type. The efficacy and safety of the formulation was established in a randomized, double-blind, placebo-controlled trial of 677 outpatients on a stable dose of acetylcholinesterase inhibitors (AChEI). The results of the study demonstrated statistically significant improvement in cognition and global function for patients treated with NAMENDA XR 28 mg plus an AChEI compared to placebo plus an AChEI. "The NAMENDA XR study supports the existing body of evidence that memantine provides cognitive and global benefits in patients with moderate to severe Alzheimer's disease either alone or with an AChEI," said Dr. Marco Taglietti, President of Forest Research Institute. The Full Research Report on Forest Laboratories, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/e121_FRX] -- Pharmacyclics,Inc. Research Report On June 16, 2013, Pharmacyclics, Inc. (Pharmacyclics) announced the results of two separate Phase 2 studies suggesting that ibrutnib showed efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL). The Company sponsored both studies and is jointly developing ibrutnib with Janssen Research & Development, LLC. The findings at EHA for patients with MCL or DLBCL expand on the results reported by investigators in 2012. Among patients with relapsed/refractory MCL, ibrutnib achieved an overall response rate (ORR) of 68%, including a complete response (CR) of 21% where all signs of cancer are gone, and a partial response (PR) of 47%. In the second study among relapsed/refractory DLBCL patients, investigators examined whether ibrutinib would be more active in the Activated B-cell-like (ABC) subtype of DBCL compared to those with the Germinal Center B-Cell-like (GCB) subtype. Results revealed that patients with the ABC subtype showed a preferential response to ibrutinib monotherapy compared to those with the GCB subtype, with ORR response rate of 41% vs. 5%, respectively. The Full Research Report on Pharmacyclics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/dd7a_PCYC] -- Cubist Pharmaceuticals,Inc. Research Report On June 13, 2013, Cubist Pharmaceuticals, Inc. (Cubist) announced the appointment of Dr. Lorianne Masuoka as Chief Medical Officer and Senior Vice President of Clinical Development and Medical Affairs. With the new appointment, Dr. Masuoka will lead the strategy, development, and implementation of the Company's global clinical programs, while overseeing Clinical Research, Medical Affairs, Clinical Operations, Biostatistics, Data Management, and Pharmacovigilance. "Dr. Masuoka brings to Cubist a great blend of medical and scientific leadership, diversity of therapeutic area experience, and global management skills," said Steven Gilman, Ph.D., Executive Vice President of Research and Development and Chief Scientific Officer of Cubist. Dr. Masuoka has more than 25 years of global medical and development experience. Previously, she has served in many roles, including as Senior Vice President and Chief Medical Officer at Nektar Therapeutics, VP of Clinical Development at Fiveprime Therapeutics, and Director of Clinical Development at Chiron. The Full Research Report on Cubist Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/92f0_CBST] -- Dr. Reddy's Laboratories Limited Research Report On June 3, 2013, Dr. Reddy's Laboratories Limited (Dr. Reddy's) and Fujifilm Corporation (Fujifilm) announced the termination of their Memorandum of Understanding (MoU) to enter into an exclusive partnership in the generic drugs business for the Japanese market and to establish a joint venture in Japan. The MoU was signed on July 28, 2011, based on which the two Companies had conducted detailed studies on the establishment of a joint venture for developing and manufacturing generic drugs in Japan. However, the Company stated that as Fujifilm is realigning its long-term growth strategy, both Companies have agreed on terminating the MoU. "Unfortunately, we will not be able to partner with Fujifilm specifically for generic formulations business in Japan. However, I want to reinforce our commitment towards a planned entry into Japan to bring affordable and innovative drugs to more patients worldwide," said GV Prasad, Chairman and CEO of Dr. Reddy's. The Full Research Report on Dr. Reddy's Laboratories Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/e286_RDY] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquires, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports
Research Abstracts, Phase 2 Results, and Market Availability of Formulations and Treatments- Research Report on Teva, Forest,
Press spacebar to pause and continue. Press esc to stop.